









Markets
/
Stocks
/
nasdaq-alks
/

Alkermes Plc

ALKS

View Detailed Chart

26.550USD

+0.060+0.23%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

4.38BMarket Cap

12.42P/E TTM



Alkermes Plc

26.550

+0.060+0.23%

Overview Company Financials

Financials

Intraday

30m

Today

+0.23%

5 Days

+1.61%

1 Month

-7.97%

6 Months

-13.69%

Year to Date

-7.68%

1 Year

-4.22%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 17 analysts

BUY

Current Rating

42.000

Target Price

58.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Alkermes Plc

ALKS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(9)

Neutral(3)

Buy(0)

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.192

Sell

RSI(14)

38.771

Neutral

STOCH(KDJ)(9,3,3)

29.574

Neutral

ATR(14)

1.088

Low Volatility

CCI(14)

-64.707

Neutral

Williams %R

80.783

Oversold

TRIX(12,20)

-0.438

Sell

StochRSI(14)

53.889

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

26.824

Sell

MA10

26.766

Sell

MA20

28.165

Sell

MA50

29.259

Sell

MA100

30.043

Sell

MA200

30.195

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Ticker SymbolALKS

CompanyAlkermes Plc

CEOMr. Richard F. Pops

Websitehttps://www.alkermes.com/